MARKET
IPO

RNAZ

Transcode Therapeutics, Inc.
RNAZ
NASDAQ
Upcoming IPOs
Expected Listing Date: 2021-05-11
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-14.48
-
-9.96
33.94M
Biotechnology & Medical Research
2021-02-26
Public Filing
View Prospectus
2021-04-20
Offering
Price Range: 8.00~10.00
Shares to be Issued: 2777.78K
2021-05-10
Offering End Date
Offering Price: 4.000
Post IPO Outstanding: 8485.08K
2021-05-11
Listed
DJ TransCode Therapeutics Boosts IPO Size, Cuts Expected Price
Dow Jones · 5d ago
News On TransCode Therapeutics Inc. (TCTI.XX) Now Under RNAZ
News On TransCode Therapeutics Inc. (TCTI.XX) Now Under RNAZ
Dow Jones · 04/23 21:08
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RNAZ. Analyze the recent business situations of Transcode Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About RNAZ
TransCode Therapeutics, Inc. is a ribonucleic acid (RNA) oncology company. The Company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer. TTX-MC138 comprises proprietary iron-oxide nanoparticles and oligonucleotides that specifically target microRNA-10b. The nanoparticles serve as the vehicle to deliver oligonucleotides to metastatic cancer cells. The magnetic properties of these nanoparticles allow for monitoring of their delivery using non-invasive imaging. Its pipeline products also include TTX-siPDL1, TTX-siLIN28b and TTX-RIGA. TTX-siPDL1 is a checkpoint inhibitor targeting programmed cell death protein ligand 1 (PD-L1). TTX-RIGA utilizes its delivery system and is intended to activate the RIG-I signaling pathway to elicit an immune response to eliminate and/or reduce the risk of developing disorders associated with abnormal apoptotic or differentiative processes, by triggering an immune response that targets developing cancer cells.

Webull offers kinds of Transcode Therapeutics, Inc. stock information, including NASDAQ:RNAZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAZ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RNAZ stock methods without spending real money on the virtual paper trading platform.